New combo therapy aims to stop oral cancer from coming back
NCT ID NCT07371611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding the immunotherapy drug sintilimab to chemotherapy before and after surgery can improve outcomes for people with advanced oral cancer. About 104 participants will be randomly assigned to receive either the combination therapy or standard surgery with or without radiation. The main goal is to see if the new approach delays cancer recurrence or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sintilimab (an immunotherapy drug) combined with chemotherapy drugs (nab-paclitaxel, carboplatin, cisplatin)
- What this could lead to
- If successful, this could offer a new standard treatment that lowers the chance of oral cancer returning or spreading after surgery.
- What could go wrong
- This is a relatively small phase 3 trial (104 people), and immunotherapy can cause immune-related side effects. The added benefit over current treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED ORAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510123, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple test spot oral cancer and gum disease early?
- Less may be more: testing a gentler neck dissection for oral cancer
- Saliva test may reveal hidden spread of oral cancer
- New study tests safer pain relief for oral cancer patients
- New drug duo aims to shrink oral cancers before surgery
- Immunotherapy before surgery shows promise for oral cancer